Central Nervous System (CNS) Biomarkers: Technologies and Global Markets

Report Highlights

The global CNS biomarker market was estimated at $1.7 billion in 2011 and nearly $2 billion in 2012. The market is projected to reach $5.1 billion by the end of the forecast period of 2012 to 2017, representing a compound annual growth rate (CAGR) of 20.7%.

Report Includes

• An overview of the global market for central nervous system (CNS) biomarkers, which are measurable and quantifiable biological indicators that can be used to diagnose or predict disease, monitor disease progression, and predict treatment response.
• Analyses of global market trends, with data from 2010 through 2012, and projections of compound annual growth rates (CAGRs) through 2017.
• Evaluations of technologies such as genomics, proteomics, and imaging, and assessments of their advantages and disadvantages.
• Discussion of CNS disease segments, prevalence, and gaps in treatment for Alzheimer’s disease, depression, Parkinson’s disease, multiple sclerosis, and others.
• Patent analyses.
• Comprehensive company profiles of major players.

Report Scope

Current and projected product forecasts during the forecast period of 2012 to 2017 are discussed.  New product launches will be discussed.  Revenue figures for 2011 are actual figures.  Revenue figures for 2012 are actual figures except where actual results have not been reported, due to the timing of the release of the report.

The report includes an analysis of leading and emerging CNS biomarkers and related drugs for each CNS disorder.  Profiles of producers of leading products and their specific products are provided.  The report also assesses companies poised to introduce products during the forecast period and discusses how these introductions will change the face of the competitive environment.  The competitive environment is examined with a special focus on how new products will alter the quality of life of patients receiving CNS biomarker diagnostics and treatment with associated drugs.

Market figures are based on revenues at the manufacturers’ level and are projected at a 2012-dollar value.  Inflation is not computed into the projection figures.  Trends are assessed based on projected sales for existing products, for new product introductions, expanded markets for existing products and other factors affecting the market.

Included in this report are forecasts by product, product category and by company from 2012 through 2017.  The study is arranged to offer an overview of existing biomarker technology, drug markets for CNS diseases, drug and disease mechanism of action and companies, with forecasts broken down and covered by geographic region or country.

Patent and clinical trial information is reviewed for various candidate biomarkers.  The status of approval by the FDA and regulatory agencies in other countries of biomarker diagnostics in each segment is reviewed.

Figures are reported in U.S. dollars and in each case reflect currency fluctuations within the performance of revenue change.  Revenue figures do not account for variation in local currencies.

All market share data presented is on a global basis, unless specifically noted.

Analyst Credentials

Jackson Highsmith is a life sciences research consultant with more than 16 years of research experience. Jackson has been consulting with specialty pharmaceuticals and large pharmaceutical industry players since 2007. Prior to that, he worked at a large research consultancy, where he focused on in-depth research; he also has worked at a large pharmaceutical company in a wide range of medical therapeutics in early- and mid-stage drug development. Jackson Highsmith is a pseudonym of the author.